natgillin/translations-raw huggingface dataset:
Patients who have taken more ZYPREXA than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila ZYPREXA, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more ZYPREXA VELOTAB than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila ZYPREXA VELOTAB, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken very high doses of AMMONAPS experienced:
Pri bolnikih, ki so vzeli zelo velike odmerke zdravila AMMONAPS, so se pojavili:
Patients who have taken very high doses of sodium phenylbutyrate experienced:
Pri bolnikih, ki so vzeli zelo velike odmerke natrijevega fenilbutirata, so se pojavili:
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.
Pri bolniki, ki so bili predhodno izpostavljeni dolgotrajni mielosupresivni terapiji, se lahko zgodi, da ni bilo zbranih dovolj matičnih celic iz periferne krvi, da bi dosegli njihovo minimalno število (2,0 x 106 CD34+ celic/kg) ali pospešeno tvorjenje trombocitov v enaki meri.
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.
Pri bolnikih, ki so prejemali zelo obsežno predhodno mielosupresivno zdravljenje, se lahko zgodi, da izplavljanje PBPC ne zadošča za doseganje priporočenega najmanjšega deleža celic (2,0 x 106 celic CD34+/kg) ali za pospešitev obnove trombocitov na enako raven.
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (≥ 2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.
Pri bolnikih, ki so bili deležni zelo obsežnega predhodnega mielosupresivnega zdravljenja, se lahko zgodi, da izplavljanje matičnih celic v periferno kri ne zadošča za doseganje priporočenega najmanjšega deleža celic (≥ 2,0 x 106 CD34+ celic/kg) ali za pospešitev obnove trombocitov v enaki meri.
Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (≥ 2.0 x 106 CD34+ cells/kg) or acceleration of platelet recovery, to the same degree.
Pri bolnikih, ki so imeli zelo obsežno predhodno mielosupresivno zdravljenje, morda ne bo prišlo do zadostne mobilizacije krvotvornih matičnih celic v periferno kri, da bi dosegli najmanjši priporočeni delež celic (≥ 2,0 x 106 CD34+ celic/kg) oziroma pospešili povečevanje števila trombocitov v enaki meri.
Patients who have undetectable HCV-RNA at treatment week 12, treatment should be continued for another nine month period (i.e., a total of 48 weeks).
Bolniki, ki imajo nemerljivo koncentracijo HCV-RNA v 12. tednu zdravljenja, naj nadaljujejo z zdravljenjem še eno 9-mesečno obdobje (tj. skupaj 48 tednov).
patients who have unstable angina (a severe type of chest pain that varies in intensity); patients who have already had a non-Q-wave myocardial infarction (a type of heart attack), with chest pain in the last 24 hours and with abnormalities on the electrocardiogram (ECG) or signs of heart problems in the blood.
bolnikih z nestabilno angino pektoris (hudo bolečino v prsnem košu, katere jakost se spreminja); bolnikih, ki so imeli miokardni infarkt brez zobca Q (vrsta srčnega napada), pri katerih so v zadnjih 24 urah bile prisotne bolečine v prsnem košu ter kažejo odstopanja od normalnega elektrokardiograma (EKG) ali znake v krvi, ki nakazujejo na težave s srcem.
patients who have unstable angina (chest pain caused by poor blood flow to the heart, that may occur at rest or without an obvious trigger); patients who have already had a non-Q-wave myocardial infarction (a type of heart attack), with chest pain in the last 24 hours and with abnormalities on the electrocardiogram (ECG) or signs of heart problems in the blood.
bolnikih, ki imajo nestabilno angino pektoris (bolečine v prsnem košu zaradi slabega pretoka krvi v srce, ki se lahko pojavijo med počitkom ali brez očitnega sprožila); bolnikih, ki so imeli miokardni infarkt brez zobca Q (vrsta srčnega napada), pri katerih so v zadnjih 24 urah bile prisotne bolečine v prsnem košu ter kažejo odstopanja od normalnega elektrokardiograma (EKG) ali znake v krvi, ki nakazujejo na težave s srcem.
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing regimen using the two week lead-in period of Viramune immediate-release.
Bolniki, ki prekinejo jemanje nevirapina za več kot 7 dni, lahko nadaljujejo jemanje po priporočeni shemi odmerjanja po dvotedenskem uvajalnem obdobju z zdravilom Viramune s takojšnjim sproščanjem.
Patients who maintained PASI 75 response at Week 33 and were originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg Humira every other week or placebo for an additional 19 weeks.
33. teden ohranjen odziv PASI  75 in so bili v obdobju A randomizirani na aktivno terapijo, so med obdobjem C ponovno randomizirali tako, da so dodatnih 19 tednov dobivali 40 mg zdravila Humira vsak drugi teden ali placebo.
Patients who met all of the criteria for a CR except for recovery of platelet counts to > 100 x 109/l
Bolniki, ki izpolnjujejo vsa merila za PR, razen obnovitve števila trombocitov na > 100 x 109/l
Patients who miss a dose should be advised to inject the next dose of Cimzia as soon as they remember and then continue injecting subsequent doses as originally instructed.
Bolnikom, ki so izpustili odmerek, svetujemo, da si naslednji odmerek zdravila Cimzia vbrizgajo takoj, ko je to mogoče, ter nato z aplikacijo nadaljnjih odmerkov nadaljujejo po osnovnih navodilih.
Patients who need high volumes of parenteral nutrition may benefit from a significant reduction, whereas patients in need of low amounts may have the chance to be weaned off completely.
Bolniki, ki potrebujejo velike volumne parenteralne prehrane, bodo mogoče lahko le-te znatno zmanjšali, pri bolnikih, ki potrebujejo majhne količine, pa bo mogoče možna popolna ukinitev tovrstne prehrane.
Patients who need to adjust the dose of abacavir or lamivudine should take the medicines separately.
Bolniki, pri katerih je treba odmerka abakavirja ali lamivudina prilagoditi, morajo zdravili jemati ločeno.
Patients who never smoked had a much greater benefit from erlotinib (survival HR = 0.42, 95% CI 0.28-0.64) compared with current or ex-smokers (HR = 0.87, 95% CI 0.71-1.05).
Bolnikom, ki niso nikoli kadili, je erlotinib veliko bolj koristil (HR preživetja = 0,42, 95-% interval zaupanja: 0,28–0,64) kakor bolnikom, ki še kadijo ali so kadili (HR = 0,87, 95-% interval zaupanja: 0,71–1,05).
Patients who presented with cardiac events within 12 months prior to sunitinib administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib clinical studies.
V klinične študije sunitiniba niso bili vključeni bolniki, ki so imeli v 12 mesecih pred aplikacijo sunitiniba kakšen srčni dogodek, npr. miokardni infarkt (vključno s hudo/nestabilno angino pektoris), obvodno operacijo koronarne ali periferne arterije, simptomatsko kongestivno srčno popuščanje, cerebrovaskularni insult ali prehodno možgansko ishemijo ali pljučno embolijo.
Patients who presented with pulmonary embolism within the previous 12 months were excluded from sunitinib clinical studies.
V klinične študije s sunitinibom niso bili vključeni bolniki, ki so imeli pljučno embolijo v zadnjih 12 mesecih.
Patients who receive Humira must be given a special alert card that summarises the safety information about the medicine.
Bolniki, ki prejemajo zdravilo Humira, morajo dobiti posebno opozorilno izkaznico, ki povzema varnostne podatke o zdravilu.
Patients who receive Orencia are given a special alert card explaining that Orencia must not be used in patients with certain infections and instructing patients to contact their doctor immediately if they develop an infection during a course of treatment.
Bolniki, ki prejemajo zdravilo Orencia, bodo dobili posebno opozorilno kartico, ki pojasnjuje, da se zdravilo Orencia ne sme uporabljati pri bolnikih z določenimi okužbami, ter bolnike opominja, naj nemudoma stopijo v stik z zdravnikom, če se pri njih med zdravljenjem pojavi okužba.
Patients who receive Remicade must be given a special alert card that summarises the safety information about the medicine.
Bolniki, ki prejemajo zdravilo Remicade, morajo prejeti posebno opozorilno izkaznico, na kateri so povzeti podatki o varnosti zdravila.
Patients who receive Remsima must be given a special alert card that summarises the safety information about the medicine.
Bolniki, ki prejemajo zdravilo Remsima, morajo prejeti posebno opozorilno kartico, na kateri so povzete informacije o varnosti zdravila.
Patients who receive Soliris must be given a special card that explains the symptoms of certain types of infection, instructing them to seek medical care immediately if they experience them.
Bolniki, ki prejemajo zdravilo Soliris, morajo dobiti posebno kartico, ki vsebuje razlago simptomov določenih vrst okužb in navodilo, naj ob pojavu teh simptomov nemudoma poiščejo medicinsko pomoč.
Patients who received Afinitor and best supportive treatments were compared with patients who received placebo (a dummy treatment) and best supportive treatments to relieve disease symptoms.
Bolnike, ki so prejemali zdravilo Afinitor in najboljše podporno zdravljenje, so primerjali z bolniki, ki so prejemali placebo (zdravilo brez zdravilne učinkovine) in najboljše podporno zdravljenje za lajšanje simptomov bolezni.
Patients who received at least one dose of study medication and who had a positive culture for Candida species from a normally sterile site before study entry were included in the modified intent- to-treat (MITT) population.
Bolniki, ki so dobili vsaj en odmerek raziskovanega zdravila in so imeli pozitivno kulturo za Candida species z normalno sterilnega mesta pred vstopom v študijo, so bili vključeni v modificirano populacijo z-namenom-zdravljenja (MITT – Modified Intention To Treat).
Patients who received Cerdelga also showed an improvement of other signs of the disease such as a reduction in liver size and increased levels of haemoglobin (the protein found in red blood cells that carries oxygen around the body).
Pri bolnikih, ki so prejemali zdravilo Cerdelga, je bilo opaziti tudi izboljšanje drugih znakov bolezni, na primer zmanjšanje velikosti jeter in zvišanje ravni hemoglobina (beljakovine v rdečih krvničkah, ki prenaša kisik po telesu).
Patients who received concomitant TMZ and RT in a pilot trial for the prolonged 42 day schedule were shown to be at particular risk for developing Pneumocystis jirovecii pneumonia (PCP).
Pri bolnikih, ki so prejemali TMZ sočasno z RT v pilotnem preskušanju s podaljšanim 42-dnevnim zdravljenjem, se je izkazalo, da obstaja posebej veliko tveganje za razvoj pljučnice, ki jo povzroča Pneumocystis jirovecii (PCP).
Patients who received concomitant TMZ and RT in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing Pneumocystis jirovecii pneumonia (PCP).
Pri bolnikih, ki so prejemali TMZ sočasno z RT v pilotnem preskušanju s podaljšanim 42-dnevnim zdravljenjem, se je izkazalo, da obstaja posebej veliko tveganje za razvoj pljučnice, ki jo povzroča Pneumocystis jirovecii (PCP).
Patients who received concomitant TMZ and RT in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing Pneumocystis jiroveciipneumonia (PCP).
Pilotno preskušanje podaljšane 42-dnevne sheme zdravljenja je pokazalo, da pri bolnikih, ki so sočasno prejemali TMZ in RT, obstaja še posebej veliko tveganje za nastanek pljučnice zaradi okužbe s Pneumocystis jirovecii (PCP).
Patients who received concomitant TMZ and RT in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing Pneumocystis jirovrcci pneumonia (PCP).
Pri bolnikih, ki so prejemali TMZ sočasno z RT v pilotnem preskušanju s podaljšanim 42-dnevnim zdravljenjem, se je izkazalo, da obstaja posebej veliko tveganje za razvoj pljučnice, ki jo povzroča Pneumocystis jirovecii (PCP).
Patients who received one course of PDT had a greater risk of progression to cancer than patients who received two or three courses of PDT (50% vs.
Pri bolnikih, ki so prejeli samo eno epizodo PDT, je bilo tveganje razvoja raka večje kot pri bolnikih, ki so prejeli 2 ali 3 epizode PDT (50% proti 39 oz.
Patients who received other treatment for hyponatraemia or medicinal products which increase serum sodium concentration (see section 4.5) prior to initiation of treatment with Samsca should be managed very cautiously.
Bolnike, ki so pred začetkom zdravljenja z zdravilom Samsca prejemali druge oblike zdravljenja za hiponatriemijo ali druga zdravila, ki povečujejo koncentracije natrija v serumu (glejte poglavje 4.5), je treba obravnavati zelo skrbno.
Patients who respond to induction treatment (i.e. the initial 6 treatment cycles) with Gazyvaro in combination with bendamustine or have stable disease should continue to receive Gazyvaro 1,000 mg as single agent maintenance therapy once every 2 months for two years or until disease progression (whichever occurs first).
Bolniki, ki se odzovejo na indukcijsko zdravljenje (tj. na prvih 6 ciklusov zdravljenja) z zdravilom Gazyvaro v kombinaciji z bendamustinom ali imajo stabilno bolezen, morajo še naprej prejemati monoterapijo z zdravilom Gazyvaro 1.000 mg kot vzdrževalno zdravljenje enkrat na 2 meseca v obdobju dveh let ali do napredovanja bolezni (kar se zgodi prej).
Patients who respond to induction treatment (i.e. the initial 6 treatment cycles) with Gazyvaro in combination with bendamustine or have stable disease should continue to receive Gazyvaro 1,000 mg as single agent maintenance therapy once every 2 months for two years or until disease progression (whichever occurs first).
Bolniki, ki se odzovejo na indukcijsko zdravljenje (tj. na prvih 6 ciklusov zdravljenja) z zdravilom Gazyvaro v kombinaciji z bendamustinom ali imajo stabilno bolezen, morajo še naprej prejemati monoterapijo z zdravilom Gazyvaro 1000 mg kot vzdrževalno zdravljenje enkrat na 2 meseca v obdobju dveh let ali do napredovanja bolezni (kar se zgodi prej).
Patients who respond to treatment, may continue to receive 1,000 mg Gazyvaro once every two months for two years or as long as they benefit from it.
Bolniki, ki se odzovejo na zdravljenje, lahko še naprej prejemajo 1 000-miligramski odmerek enkrat vsake dva meseca dve leti ali dokler jim zdravilo Gazyvaro koristi.
Patients who responded to treatment were then given either Ilaris or placebo (a dummy treatment) every eight weeks for the next 24 weeks.
Bolniki, ki so se odzvali na zdravljenje, so nato naslednjih 24 tednov vsakih osem tednov prejemali bodisi zdravilo Ilaris bodisi placebo (zdravilo brez zdravilne učinkovine).
patients who should not be receiving cisplatin.
bolniki, ki ne smejo prejemati cisplatina.
Patients who still have detectable levels of HCV-RNA despite an initial 24 weeks of therapy, should discontinue therapy, as it is unlikely they will be able to achieve a sustained virological response with continued therapy.
Bolniki, ki še imajo merljivo koncentracijo HCV-RNA kljub 24 tedenskemu zdravljenju, naj z zdravljenjem prekinejo, saj je malo verjetno, da bi z nadaljevanjem zdravljenja dosegli trajen virološki odziv.
Patients who stopped smoking by Week 12 were then randomised to receive either CHAMPIX (1 mg twice daily) or placebo for an additional 12 weeks for a total study duration of 52 weeks.
Bolniki, ki so do 12. tedna opustili kajenje, so bili nato randomizirani na prejemanje bodisi zdravila CHAMPIX (1 mg dvakrat na dan) ali placeba za dodatnih 12 tednov; celotna študija je trajala 52 tednov.
Patients who suffer from these effects must avoid driving and operating machinery.
Bolniki, ki imajo ta dva neželena učinka, naj ne vozijo in ne upravljajo s stroji.
Patients who suffer from this should avoid driving and operating machinery.
Bolnice, ki so omotične, se morajo izogibati vožnji in upravljanju s stroji.
Patients who switched
Bolniki, ki so prešli z
Patients who take an overdose of bosutinib should be observed and given appropriate supportive treatment.
Bolnike, ki so vzeli prevelik odmerek zdravila Bosulif, je treba spremljati in uvesti ustrezno podporno zdravljenje.
Patients who take Benepali must be given the special alert card that summarises important safety information about the medicine so they can recognise any serious side effects and know when to seek urgent attention from their doctor.
Bolniki, ki prejemajo zdravilo Benepali, morajo prejeti posebno opozorilno kartico s povzetkom informacij o varnosti zdravila, tako da lahko prepoznajo morebitne resne neželene učinke in vedo, kdaj naj poiščejo nujno zdravniško pomoč.
Patients who take Lysodren should receive the ‘Lysodren patient card’ that they should carry with them in case of emergency, to inform healthcare professionals (such as doctors and nurses) that they are taking the medicine.
Bolniki, ki jemljejo zdravilo Lysodren, bi morali prejeti „kartico za bolnike“, ki jo morajo nositi s seboj zaradi morebitnih nujnih primerov, v katerih bo kartica zdravstvene delavce (kot so zdravniki in medicinske sestre) opozorila, da bolnik jemlje to zdravilo.
Patients who take Ranexa must be given a ‘patient alert card’ that summarises the key safety information on the medicine.
Bolnikom, ki jemljejo zdravilo Ranexa, je treba dati posebno opozorilno kartico, ki povzema najpomembnejše informacije o varnosti zdravila.
Patients who take Stayveer must be given the special reminder card that summarises the safety information about the medicine.
Bolniki, ki jemljejo zdravilo Stayveer, morajo prejeti posebno opozorilno kartico, na kateri so povzete informacije v zvezi z varnostjo zdravila.
Patients who take Tracleer must be given the special reminder card that summarises the safety information about the medicine.
Bolniki, ki prejemajo zdravilo Tracleer, morajo dobiti posebno opozorilno izkaznico, ki povzema varnostne podatke o zdravilu.
Patients who tolerate the infusions well for several months in a clinic may be able to start having them at home.
Bolniki, ki infundiranje v bolnišnici dobro prenašajo več mesecev, ga morda lahko nadaljujejo doma.
Patients who underwent transplant after alternative therapy or relapse*
bolniki s presaditvijo po alternativnem zdravljenju ali relapsu
Patients who underwent transplant while in continued remission*
bolniki s presaditvijo med trajajočo remisijo
Patients who use TOBI Podhaler during pregnancy, or become pregnant while taking TOBI Podhaler, should be informed of the potential hazard to the foetus.
Bolnice, ki uporabljajo zdravilo TOBI Podhaler med nosečnostjo ali zanosijo v času, ko uporabljajo zdravilo TOBI Podhaler, je treba opozoriti na potencialno nevarnost za plod.
Patients who weigh more than 100 kilograms (kg) may start on a dose of 90 mg instead of 45 mg.
Bolniki, ki tehtajo več kot 100 kilogramov (kg), lahko prejmejo 90 mg namesto 45 mg.
Patients who were accidentally given too much LEMTRADA in one infusion have experienced serious reactions, such as headache, rash, low blood pressure or increased heart rate.
Pri bolnikih, ki so nenamerno prejeli preveč zdravila LEMTRADA v eni infuziji, so se pojavile resne reakcije, kot so glavobol, izpuščaj, nizek krvni tlak ali pospešeno bitje srca.
Patients who were already taking other so-called ‘small-molecule DMARDs’ such as the medicine methotrexate continued this treatment during the study.
Bolniki, ki so že jemali druge tako imenovane „nizkomolekularne DMARD“, kot je zdravilo metotreksat, so s tovrstnim zdravljenjem nadaljevali tudi med študijo.
Patients who were at least 18 years of age with histologically-proven MCL and CT-measurable disease were enrolled.
Vključili so bolnike, ki so bili stari vsaj 18 let in so imeli histološko dokazano bolezen limfom plaščnih celic, merljivo s CT.
Patients who were eligible for these studies had prior exposure to at least 3 antiretroviral medicinal product classes [≥1 nucleoside reverse transcriptase inhibitors (NRTI), ≥1 non-nucleoside reverse transcriptase inhibitors (NNRTI), ≥2 protease inhibitors (PI), and/or enfurvirtide] or documented resistance to at least one member of each class.
Bolniki, ki so bili primerni za ti študiji, so bili predhodno izpostavljeni vsaj 3 skupinam protiretrovirusnih zdravil [≥ 1 nukleozidnim zaviralcem reverzne transkriptaze, ≥ 1 nenukleozidnim zaviralcem reverzne transkriptaze, ≥ 2 zaviralcem proteaz in/ali enfurvirtidu] ali so imeli dokumentirano odpornost proti vsaj enemu pripadniku vsake od teh skupin.
Patients who were given eliglustat showed an average reduction of 28% in spleen size, compared with a 2% increase in those given placebo (a dummy treatment) after 9 months of treatment.
Pri bolnikih, ki so prejemali eliglustat, se je velikost vranice po 9 mesecih zdravljenja zmanjšala za povprečno 28 % v primerjavi z 2-odstotnim povečanjem pri tistih, ki so prejemali placebo (zdravilo brez zdravilne učinkovine).
Patients who were immunocompromised and patients with severe neutropenia were excluded from clinical trials.
Bolniki s hudo imunsko oslabelostjo in bolniki s hudo nevtropenijo niso bili vključeni v klinična preskušanja.
patients who were platelet transfusion dependent at baseline and achieved transfusion independence on treatment, the median duration of platelet transfusion independence was 10.8 months in the Vidaza group and 19.2 months in the CCR group.
Pri bolnikih, ki so bili v izhodišču odvisni od transfuzij trombocitov in so ob zdravljenju dosegli neodvisnost od transfuzij, je bilo mediano trajanje neodvisnosti od transfuzij trombocitov v skupini z zdravilom Vidaza 10,8 meseca, v skupini s CCR pa 19,2 meseca.
Patients who were previously untreated or failed at least one prior systemic therapy (Results from the Phase II [BREAK-2])
Bolniki, ki predhodno niso bili zdravljeni ali pri katerih je bilo vsaj eno predhodno sistemsko zdravljenje neuspešno (rezultati II. faze [BREAK-2])
Patients who were re-randomized to placebo and who lost PASI-75 response (ESTEEM 1) or lost 50% of the PASI improvement at Week 32 compared to baseline (ESTEEM 2) were retreated with apremilast 30 mg BID.
Bolnike, ki so bili ponovno randomizirani na placebo in ki so izgubili odziv PASI-75 (ESTEEM 1) ali ki so izgubili 50 % izboljšanja PASI v 32. tednu v primerjavi z izhodiščem (ESTEEM 2), so še enkrat zdravili z apremilastom 30 mg dvakrat na dan.
Patients who were successfully withdrawn from ciclosporin had lower serum creatinine levels and higher calculated glomerular filtration rates, as well as lower incidence of malignancy, compared to patients remaining on ciclosporin.
Bolniki, ki so jim uspešno ukinili ciklosporin, so imeli nižje koncentracije serumskega kreatinina in večjo izračunano hitrost glomerulne filtracije, pa tudi manjšo incidenco malignih bolezni kot bolniki, ki so nadaljevali zdravljenje s ciklosporini.
Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.
Bolnikom, ki nimajo previsoke koncentracije kalcija v krvi, bo zdravnik predpisal nadomestke kalcija in vitamina D, ki jih bodo jemali vsak dan..